Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Autoimmune nodopathy with anti-NF186 antibodies following SARS-CoV-2 infection: A case report

Simplified Abstract Sample Work

SARS-CoV-2 infection has been associated with various autoimmune neurological disorders. Autoimmune nodopathies, involving antibodies against neurofascin-186 (NF186), are rare conditions. These antibodies impair nodal integrity, resulting in peripheral nerve dysfunction. Reports of anti-NF186 antibody–associated neuropathy after COVID-19 infection is extremely uncommon. We present a case highlighting the post-infectious autoimmune mechanism and clinical outcome.

Nodes of Ranvier, neurofascin-186 and what goes wrong in nodopathy

Peripheral nerves conduct signals quickly because their fibres are wrapped in myelin, interrupted at regular gaps called nodes of Ranvier. Proteins clustered at and around these nodes hold the structure together and allow the electrical impulse to jump from one node to the next. Neurofascin-186 (NF186) is one such nodal protein. In autoimmune nodopathy, the immune system produces antibodies against nodal or paranodal proteins, disrupting conduction and causing weakness and sensory loss.

The simplified abstract in this sample summarises a 2025 case report by Lai and colleagues in BMC Neurology (doi:10.1186/s12883-025-04417-9) describing anti-NF186 autoimmune nodopathy following SARS-CoV-2 infection. Its background panels introduce exactly this mechanism before mentioning COVID-19, so that readers understand the disease before they meet the proposed trigger. The page is a writing sample, not medical guidance.

Placing a post-COVID neurological case in context

Since 2020, many neurological conditions have been reported after SARS-CoV-2 infection, and the evidentiary weight of these reports varies widely. The sample's knowledge-gap panel situates this case carefully: autoimmune nodopathies are recognised, but their association with viral infections, and with COVID-19 in particular, is not well established, leaving limited guidance on treating post-COVID neurological complications.

The "Here we show" panel reports the authors' position that this is the first report of anti-NF186 nodopathy associated with SARS-CoV-2 infection. A responsible summary attributes such a claim to the authors rather than stating it as settled fact, and the sample does so. It also uses the word "associated" rather than "caused", since a single temporal sequence cannot prove causation even when an immunological mechanism is plausible.

The treatment sequence as the abstract tells it

Escalating immunotherapy is the most instructive part of this case, and the sample sets it out in the order the patient received it:

  1. Assessment: detailed neurological examination; electromyography to characterise conduction defects; cell-based assays to confirm anti-NF186 antibodies.
  2. First-line therapy: intravenous immunoglobulin and steroids, with minimal improvement.
  3. Escalation: plasma exchange, followed by partial recovery.
  4. Maintenance: rituximab, a B-cell-depleting antibody, after which the patient's condition stabilised and muscle strength gradually improved.

The results panel also records how severe the illness became, with progression to respiratory muscle paralysis. Including that detail is important; without it, a reader might underestimate why the treating team moved to plasma exchange and B-cell depletion. The implications panel draws the practical conclusion the authors offer: plasma exchange or B-cell-depleting therapies such as rituximab tended to give better outcomes than conventional approaches in this setting, and anti-NF186 testing should be considered in post-COVID patients with a compatible pattern.

Correcting terminology during simplification

Neurological case reports often use closely related terms, and errors creep in easily when text is condensed. Nodopathy (disease of the node), paranodopathy, mononeuropathy (disease of a single nerve) and polyneuropathy describe different things. An editor preparing a simplified abstract should check that the disease is named consistently throughout, because a reader who encounters "nodopathy" in one panel and a different term in the next may reasonably assume two conditions are being discussed.

The same discipline applies to tests. Electromyography assesses muscle and nerve electrical activity; cell-based assays detect specific antibodies by showing whether patient serum binds cells engineered to express the target protein. Naming each test with its purpose in a short clause, as the methodological panel does, lets non-neurologists see why each was performed.

Checklist for summarising an antibody-mediated neuropathy case

Clinicians preparing their own report of an immune-mediated neuropathy can use this sample as a model for the one-page version. A practical checklist drawn from it:

  • Introduce the target antigen and its normal function before the clinical story.
  • State the proposed trigger as an association and attribute novelty claims to the authors.
  • Give treatments in sequence with the response to each, so escalation is justified on the page.
  • Record the maximum severity reached, not only the final outcome.
  • End with testing and treatment implications that answer the knowledge gap.

The full manuscript would normally be structured according to the CARE guidelines for case reports, including a timeline and follow-up. Once published, a simplified abstract makes the case accessible to rehabilitation teams, infectious disease specialists and patient groups who may not read neuromuscular journals, and a graphical abstract can show the treatment escalation as a timeline.

Questions about this sample

What is neurofascin-186 and why does it matter in this case?

Neurofascin-186 is a protein concentrated at the nodes of Ranvier, the gaps in the myelin sheath where nerve impulses are regenerated. Antibodies against it disrupt nodal structure and slow or block conduction. The case report confirmed anti-NF186 antibodies with cell-based assays, which established the diagnosis of autoimmune nodopathy.

Does the summary claim that COVID-19 caused the nodopathy?

It describes the nodopathy as following, and associated with, SARS-CoV-2 infection. A single case shows a temporal sequence and a plausible immune mechanism but cannot prove causation, so the sample avoids causal wording and attributes the claim of being the first such report to the authors.

Which treatments helped the patient, according to the sample?

Intravenous immunoglobulin and steroids produced minimal improvement. Plasma exchange led to partial recovery, and the patient's condition stabilised after rituximab was started, with muscle strength improving gradually over the course of treatment. The summary presents these steps in order so readers can see why therapy was escalated.

Why does the summary mention respiratory muscle paralysis?

It shows how severe the disease became before effective treatment. Without that detail, readers might not understand why the treating team escalated to plasma exchange and B-cell depletion. Reporting peak severity alongside the final outcome gives a more accurate picture of the clinical course.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.